Intracellular Signaling and Approaches to the Treatment of Schizophrenia and Associated Cognitive Impairment

E-ISSN： 1873-4286|20|31|5093-5103

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.31, 2014-09, pp. : 5093-5103

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction

Current Pharmaceutical Design, Vol. 21, Iss. 26, 2015-01 ,pp. : 3813-3828

Bentham Science Publishers

Access to resources Recommend Favorite

Neuronal Nicotinic Acetylcholine Receptors - Targets for the Development of Drugs to Treat Cognitive Impairment Associated with Schizophrenia and Alzheimer's Disease

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 2, 2010-02 ,pp. : 144-152

Bentham Science Publishers

Access to resources Recommend Favorite

5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia

Current Pharmaceutical Design, Vol. 21, Iss. 26, 2015-01 ,pp. : 3739-3759

Bentham Science Publishers

Access to resources Recommend Favorite

Recent advances in treating cognitive impairment in schizophrenia

By Galletly Cherrie

Psychopharmacology, Vol. 202, Iss. 1-3, 2009-01 ,pp. : 259-273

Springer Publishing Company

Access to resources Recommend Favorite

Assessing and Treating Cognitive Impairment in Schizophrenia: Current and Future

Current Pharmaceutical Design, Vol. 20, Iss. 32, 2014-10 ,pp. : 5127-5138

Bentham Science Publishers

Access to resources Recommend Favorite